PRISME FORUM SIG:

R&D IT Survey Progress (Fall 2013 Update)

Michael Shanler

Research Director, Life Science

IAS-Manufacturing

michael.shanler@gartner.com

978-443-3536 (w)

781-547-1283 (m)

© 2013 Gartner, Inc. and/or its affiliates. All rights reserved. Gartner is a registered trademark of Gartner, Inc. or its affiliates. This publication may not be reproduced or distributed in any form without Gartner's prior written permission. If you are authorized to access this publication, your use of it is subject to the Usage Guidelines for Gartner Services posted on gartner.com. The information contained in this publication has been obtained from sources believed to be reliable. Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information and shall have no liability for errors, omissions or inadequacies in such information. This publication consists of the opinions of Gartner's research organization and should not be construed as statements of fact. The opinions expressed herein are subject to change without notice. Although Gartner research may include a discussion of related legal issues, Gartner does not provide legal advice or services and its research should not be construed or used as such. Gartner is a public company, and its shareholders may include firms and funds that have financial interests in entities covered in Gartner research. Gartner's Board of Directors may include senior managers of these firms or funds. Gartner research is produced independently by its research organization without input or influence from these firms, funds or their managers. For further information on the independence and integrity of Gartner research, see "Guiding Principles on Independence and Objectivity."



Key Points

- Gartner will not share any individual data sets (with PRISME Forum SIG members, Gartner clients, external parties, etc.)
- Gartner will not publish any individual data sets, but may report on high level "trends" as it relates to groups.
- Gartner will share survey analysis results with contributing (& noncontributing (?)) PRISME Forum SIG member organizations
- Many PRISME Forum SIG member organizations are Gartner clients (IAS, CIO, EXP, SC).
- Only Gartner seat-holders can access Gartner reports
- PRISME Forum SIG data may be merged with Gartner data for reporting purposes. Organizations' data will be grouped and blinded.
- Gartner Analyst (Michael Shanler michael.shanler@gartner.com)
 will report back to PRISME Forum SIG with "Summary" Data
- Gartner Clients data may be combined with the data sets.



Timeline

CONCEPT-

Outline Scope (SUMMER, 2013)

DESIGN -

Present draft w/ PRISME Forum SIG. (OCT, 2013)

Feedback from PRISME Forum SIG (OCT, 2013)

Perform Revisions (OCT, 2013)

Design - 0.1 - Verify I/O w/ ORG A (Martin Leach, Biogen) - (NOV, 2013)

Design - 0.2 - Perform Revisions (NOV, 2013)

Expanded survey with ORGs B()&C()? - (NOV, 2013)

Internal Review (DEC, 2013) *note: to maintain confidentiality, privacy

Internal Analytics review (DEC, 2013) *

Design Freeze 0.3 w/ A,B,C (unblinded data, blinded data, or no data?)>>>(JAN, 2013)

Templating (JAN, 2013)

COLLECTION -

Collection from PRISME members (JAN-FEB, 2014)

Collection from non-PRISME (Gartner seat-holders) (JAN-MAR, 2014)


ANALYSIS -

Gartner Analytics PRISME review

Gartner Summary Review, QA/QC (PRISME)

Gartner Summary Reports (PRISME)

PRISME PRESENTATION (APRIL, 2014)





Survey has 6 main sections

- Contributor Information and Company Qualifiers
- 2012 Financials and Spending: Corporate vs all R&D
- IT Staffing: corporate, R&D IT (internal), R&D IT (contract), R&D "shadow"
- IT Spending: Corporate vs R&D, Capital R&D IT, Operational R&D IT
- Work: corporate, active R&D "projects"
- R&D IT Organization or Hierarchy

Contributors & Qualifiers

Contributor Name:	
e-mail:	
Phone:	
Title:	
Company:	
Address (City, State, Country):	
Business Unit:	

If other, then describe the business:

Info to be controlled by Gartner


COMPANY QUALIFIERS

check one

Big Pharma (> \$10B/yr revenue)
Medium Pharma (\$1-10B/yr revenue)
Small Pharma <\$1B revenue
Biotechnology (w/ active clinical trials) - How many in # ph 1, # ph2, # ph3?
Biotechnology (no active clinical trials)
Other (Institutinon, Diagnostics, Crop, Ag, Chem, CRO, etc.)

This will help "group" the data for downstream analysis.





COMPANY EMPLOYEES staff supported Q5 Q6 Subset: Total number "R&D" Total Number employees Employees at (scientists, engine ratio (R&D: Entire Company? ers, etc)? Total) 10000 800 0.08 R&D Breakdown How many "Research" employees? Q6A 400 How many "Clinical

Development"

"Development"

manufacturing?

employees?

employees supporting

FTE by FUNCTION


This data to be carrier across to each subsequent section:

- Research
- Development (Clinical)
- Development (Production)

Gartner

Q6B

Q6C



SPEND

